SPIRE – combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-12

AUTHORS

Simon Crabb, Sarah J. Danson, James W. F. Catto, Cathy McDowell, James N. Lowder, Joshua Caddy, Denise Dunkley, Jessica Rajaram, Deborah Ellis, Stephanie Hill, David Hathorn, Amy Whitehead, Mihalis Kalevras, Robert Huddart, Gareth Griffiths

ABSTRACT

BACKGROUND: Urothelial bladder cancer (UBC) accounts for 10,000 new diagnoses and 5000 deaths annually in the UK (Cancer Research UK, http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bladder-cancer , Cancer Research UK, Accessed 26 Mar 2018). Cisplatin-based chemotherapy is standard of care therapy for UBC for both palliative first-line treatment of advanced/metastatic disease and radical neoadjuvant treatment of localised muscle invasive bladder cancer. However, cisplatin resistance remains a critical cause of treatment failure and a barrier to therapeutic advance in UBC. Based on supportive pre-clinical data, we hypothesised that DNA methyltransferase inhibition would circumvent cisplatin resistance in UBC and potentially other cancers. METHODS: The addition of SGI-110 (guadecitabine, a DNA methyltransferase inhibitor) to conventional doublet therapy of gemcitabine and cisplatin (GC) is being tested within the phase Ib/IIa SPIRE clinical trial. SPIRE incorporates an initial, modified rolling six-dose escalation phase Ib design of up to 36 patients with advanced solid tumours followed by a 20-patient open-label randomised controlled dose expansion phase IIa component as neoadjuvant treatment for UBC. Patients are being recruited from UK secondary care sites. The dose escalation phase will determine a recommended phase II dose (RP2D, primary endpoint) of SGI-110, by subcutaneous injection, on days 1-5 for combination with GC at conventional doses (cisplatin 70 mg/m2, IV infusion, day 8; gemcitabine 1000 mg/m2, IV infusion, days 8 and 15) in every 21-day cycle. In the dose expansion phase, patients will be randomised 1:1 to GC with or without SGI-110 at the proposed RP2D. Secondary endpoints will include toxicity profiles, SGI-110 pharmacokinetics and pharmacodynamic biomarkers, and pathological complete response rates in the dose expansion phase. Analyses will not be powered for formal statistical comparisons and descriptive statistics will be used to describe rates of toxicity, efficacy and translational endpoints by treatment arm. DISCUSSION: SPIRE will provide evidence for whether SGI-110 in combination with GC chemotherapy is safe and biologically effective prior to future phase II/III trials as a neoadjuvant therapy for UBC and potentially in other cancers treated with GC. TRIAL REGISTRATION: EudraCT Number: 2015-004062-29 (entered Dec 7, 2015) ISRCTN registry number: 16332228 (registered on Feb 3, 2016). More... »

PAGES

216

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13063-018-2586-7

DOI

http://dx.doi.org/10.1186/s13063-018-2586-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1103148487

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29615077


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Southampton", 
          "id": "https://www.grid.ac/institutes/grid.5491.9", 
          "name": [
            "Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Crabb", 
        "givenName": "Simon", 
        "id": "sg:person.01205711374.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01205711374.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Sheffield", 
          "id": "https://www.grid.ac/institutes/grid.11835.3e", 
          "name": [
            "Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Sheffield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Danson", 
        "givenName": "Sarah J.", 
        "id": "sg:person.0727040356.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0727040356.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Sheffield", 
          "id": "https://www.grid.ac/institutes/grid.11835.3e", 
          "name": [
            "Academic Urology Unit, The Medical school, University of Sheffield, Sheffield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Catto", 
        "givenName": "James W. F.", 
        "id": "sg:person.013571313737.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013571313737.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cancer Research UK", 
          "id": "https://www.grid.ac/institutes/grid.11485.39", 
          "name": [
            "Cancer Research UK, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McDowell", 
        "givenName": "Cathy", 
        "id": "sg:person.015145616762.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015145616762.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Astellas Pharma (United States)", 
          "id": "https://www.grid.ac/institutes/grid.423286.9", 
          "name": [
            "Astex Pharmaceuticals, Inc., Pleasanton, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lowder", 
        "givenName": "James N.", 
        "id": "sg:person.01067561552.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067561552.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Southampton", 
          "id": "https://www.grid.ac/institutes/grid.5491.9", 
          "name": [
            "Southampton Clinical Trials Unit, Centre for Cancer Immunology, University of Southampton, Southampton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Caddy", 
        "givenName": "Joshua", 
        "id": "sg:person.016540557762.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016540557762.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Southampton", 
          "id": "https://www.grid.ac/institutes/grid.5491.9", 
          "name": [
            "Southampton Clinical Trials Unit, Centre for Cancer Immunology, University of Southampton, Southampton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dunkley", 
        "givenName": "Denise", 
        "id": "sg:person.010035506562.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010035506562.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Southampton", 
          "id": "https://www.grid.ac/institutes/grid.5491.9", 
          "name": [
            "Southampton Clinical Trials Unit, Centre for Cancer Immunology, University of Southampton, Southampton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rajaram", 
        "givenName": "Jessica", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Southampton", 
          "id": "https://www.grid.ac/institutes/grid.5491.9", 
          "name": [
            "Southampton Clinical Trials Unit, Centre for Cancer Immunology, University of Southampton, Southampton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ellis", 
        "givenName": "Deborah", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Southampton", 
          "id": "https://www.grid.ac/institutes/grid.5491.9", 
          "name": [
            "Southampton Clinical Trials Unit, Centre for Cancer Immunology, University of Southampton, Southampton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hill", 
        "givenName": "Stephanie", 
        "id": "sg:person.012226030162.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012226030162.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Southampton", 
          "id": "https://www.grid.ac/institutes/grid.5491.9", 
          "name": [
            "Southampton Clinical Trials Unit, Centre for Cancer Immunology, University of Southampton, Southampton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hathorn", 
        "givenName": "David", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Southampton", 
          "id": "https://www.grid.ac/institutes/grid.5491.9", 
          "name": [
            "Southampton Clinical Trials Unit, Centre for Cancer Immunology, University of Southampton, Southampton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Whitehead", 
        "givenName": "Amy", 
        "id": "sg:person.010355406303.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010355406303.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Southampton", 
          "id": "https://www.grid.ac/institutes/grid.5491.9", 
          "name": [
            "Southampton Clinical Trials Unit, Centre for Cancer Immunology, University of Southampton, Southampton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kalevras", 
        "givenName": "Mihalis", 
        "id": "sg:person.07427543430.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07427543430.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Cancer Research", 
          "id": "https://www.grid.ac/institutes/grid.18886.3f", 
          "name": [
            "The Institute of Cancer Research, Sutton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Huddart", 
        "givenName": "Robert", 
        "id": "sg:person.0607741761.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607741761.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Southampton", 
          "id": "https://www.grid.ac/institutes/grid.5491.9", 
          "name": [
            "Southampton Clinical Trials Unit, Centre for Cancer Immunology, University of Southampton, Southampton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Griffiths", 
        "givenName": "Gareth", 
        "id": "sg:person.0745007670.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0745007670.05"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-13-2805", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006902149"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.urolonc.2009.09.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008466352"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-09-3427", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012230767"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(15)00038-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016223038"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa022148", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017518186"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.urology.2007.11.029", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017900311"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.exphem.2012.06.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020992592"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-11-3909", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026504828"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.07.757", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028324313"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.07.757", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028324313"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/95.5.399", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032079551"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.06161-11", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036456002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6603482", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041715325", 
          "https://doi.org/10.1038/sj.bjc.6603482"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6603482", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041715325", 
          "https://doi.org/10.1038/sj.bjc.6603482"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.eururo.2005.04.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041745561"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.10.8688", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042356249"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0032750", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045055578"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.12.7712", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046116901"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.32.3139", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048003021"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1089/cbr.2012.1303", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059243296"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2174/1574885511005010017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069214672"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/ijmm.2012.1138", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071507284"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/ijo.2011.1049", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071512325"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/ijo.2014.2792", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071513765"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/ijo.2014.2792", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071513765"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4161/15384047.2014.986967", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072288033"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4161/epi.4.3.8694", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072302907"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-158-3-201302050-00583", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073713447"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2000.18.17.3068", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074702294"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078479667", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1613683", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083846671"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(17)30576-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091339395"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(17)30576-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091339395"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12", 
    "datePublishedReg": "2018-12-01", 
    "description": "BACKGROUND: Urothelial bladder cancer (UBC) accounts for 10,000 new diagnoses and 5000 deaths annually in the UK (Cancer Research UK, http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bladder-cancer , Cancer Research UK, Accessed 26 Mar 2018). Cisplatin-based chemotherapy is standard of care therapy for UBC for both palliative first-line treatment of advanced/metastatic disease and radical neoadjuvant treatment of localised muscle invasive bladder cancer. However, cisplatin resistance remains a critical cause of treatment failure and a barrier to therapeutic advance in UBC. Based on supportive pre-clinical data, we hypothesised that DNA methyltransferase inhibition would circumvent cisplatin resistance in UBC and potentially other cancers.\nMETHODS: The addition of SGI-110 (guadecitabine, a DNA methyltransferase inhibitor) to conventional doublet therapy of gemcitabine and cisplatin (GC) is being tested within the phase Ib/IIa SPIRE clinical trial. SPIRE incorporates an initial, modified rolling six-dose escalation phase Ib design of up to 36 patients with advanced solid tumours followed by a 20-patient open-label randomised controlled dose expansion phase IIa component as neoadjuvant treatment for UBC. Patients are being recruited from UK secondary care sites. The dose escalation phase will determine a recommended phase II dose (RP2D, primary endpoint) of SGI-110, by subcutaneous injection, on days 1-5 for combination with GC at conventional doses (cisplatin 70 mg/m2, IV infusion, day 8; gemcitabine 1000 mg/m2, IV infusion, days 8 and 15) in every 21-day cycle. In the dose expansion phase, patients will be randomised 1:1 to GC with or without SGI-110 at the proposed RP2D. Secondary endpoints will include toxicity profiles, SGI-110 pharmacokinetics and pharmacodynamic biomarkers, and pathological complete response rates in the dose expansion phase. Analyses will not be powered for formal statistical comparisons and descriptive statistics will be used to describe rates of toxicity, efficacy and translational endpoints by treatment arm.\nDISCUSSION: SPIRE will provide evidence for whether SGI-110 in combination with GC chemotherapy is safe and biologically effective prior to future phase II/III trials as a neoadjuvant therapy for UBC and potentially in other cancers treated with GC.\nTRIAL REGISTRATION: EudraCT Number: 2015-004062-29 (entered Dec 7, 2015) ISRCTN registry number: 16332228 (registered on Feb 3, 2016).", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s13063-018-2586-7", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.5137510", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1297400", 
        "issn": [
          "1468-6708", 
          "1745-6215"
        ], 
        "name": "Trials", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "name": "SPIRE \u2013 combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial", 
    "pagination": "216", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13063-018-2586-7"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "231725dcbfe8dee320517b7c97f34b17b1dcadd64d0894bc713fb4000b163998"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1103148487"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101263253"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29615077"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13063-018-2586-7", 
      "https://app.dimensions.ai/details/publication/pub.1103148487"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-15T09:08", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000376_0000000376/records_56154_00000004.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs13063-018-2586-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13063-018-2586-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13063-018-2586-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13063-018-2586-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13063-018-2586-7'


 

This table displays all metadata directly associated to this object as RDF triples.

267 TRIPLES      21 PREDICATES      58 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13063-018-2586-7 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N6127859b3d81412fa6b1c0e698220e4d
4 schema:citation sg:pub.10.1038/sj.bjc.6603482
5 https://app.dimensions.ai/details/publication/pub.1078479667
6 https://doi.org/10.1016/j.eururo.2005.04.006
7 https://doi.org/10.1016/j.exphem.2012.06.001
8 https://doi.org/10.1016/j.urology.2007.11.029
9 https://doi.org/10.1016/j.urolonc.2009.09.015
10 https://doi.org/10.1016/s1470-2045(15)00038-8
11 https://doi.org/10.1016/s1470-2045(17)30576-4
12 https://doi.org/10.1056/nejmoa022148
13 https://doi.org/10.1056/nejmoa1613683
14 https://doi.org/10.1089/cbr.2012.1303
15 https://doi.org/10.1093/jnci/95.5.399
16 https://doi.org/10.1128/aac.06161-11
17 https://doi.org/10.1158/0008-5472.can-09-3427
18 https://doi.org/10.1158/0008-5472.can-11-3909
19 https://doi.org/10.1158/1078-0432.ccr-13-2805
20 https://doi.org/10.1200/jco.2000.18.17.3068
21 https://doi.org/10.1200/jco.2005.07.757
22 https://doi.org/10.1200/jco.2007.10.8688
23 https://doi.org/10.1200/jco.2007.12.7712
24 https://doi.org/10.1200/jco.2010.32.3139
25 https://doi.org/10.1371/journal.pone.0032750
26 https://doi.org/10.2174/1574885511005010017
27 https://doi.org/10.3892/ijmm.2012.1138
28 https://doi.org/10.3892/ijo.2011.1049
29 https://doi.org/10.3892/ijo.2014.2792
30 https://doi.org/10.4161/15384047.2014.986967
31 https://doi.org/10.4161/epi.4.3.8694
32 https://doi.org/10.7326/0003-4819-158-3-201302050-00583
33 schema:datePublished 2018-12
34 schema:datePublishedReg 2018-12-01
35 schema:description BACKGROUND: Urothelial bladder cancer (UBC) accounts for 10,000 new diagnoses and 5000 deaths annually in the UK (Cancer Research UK, http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bladder-cancer , Cancer Research UK, Accessed 26 Mar 2018). Cisplatin-based chemotherapy is standard of care therapy for UBC for both palliative first-line treatment of advanced/metastatic disease and radical neoadjuvant treatment of localised muscle invasive bladder cancer. However, cisplatin resistance remains a critical cause of treatment failure and a barrier to therapeutic advance in UBC. Based on supportive pre-clinical data, we hypothesised that DNA methyltransferase inhibition would circumvent cisplatin resistance in UBC and potentially other cancers. METHODS: The addition of SGI-110 (guadecitabine, a DNA methyltransferase inhibitor) to conventional doublet therapy of gemcitabine and cisplatin (GC) is being tested within the phase Ib/IIa SPIRE clinical trial. SPIRE incorporates an initial, modified rolling six-dose escalation phase Ib design of up to 36 patients with advanced solid tumours followed by a 20-patient open-label randomised controlled dose expansion phase IIa component as neoadjuvant treatment for UBC. Patients are being recruited from UK secondary care sites. The dose escalation phase will determine a recommended phase II dose (RP2D, primary endpoint) of SGI-110, by subcutaneous injection, on days 1-5 for combination with GC at conventional doses (cisplatin 70 mg/m2, IV infusion, day 8; gemcitabine 1000 mg/m2, IV infusion, days 8 and 15) in every 21-day cycle. In the dose expansion phase, patients will be randomised 1:1 to GC with or without SGI-110 at the proposed RP2D. Secondary endpoints will include toxicity profiles, SGI-110 pharmacokinetics and pharmacodynamic biomarkers, and pathological complete response rates in the dose expansion phase. Analyses will not be powered for formal statistical comparisons and descriptive statistics will be used to describe rates of toxicity, efficacy and translational endpoints by treatment arm. DISCUSSION: SPIRE will provide evidence for whether SGI-110 in combination with GC chemotherapy is safe and biologically effective prior to future phase II/III trials as a neoadjuvant therapy for UBC and potentially in other cancers treated with GC. TRIAL REGISTRATION: EudraCT Number: 2015-004062-29 (entered Dec 7, 2015) ISRCTN registry number: 16332228 (registered on Feb 3, 2016).
36 schema:genre research_article
37 schema:inLanguage en
38 schema:isAccessibleForFree true
39 schema:isPartOf N4d22e6fc79af41ff92b68953caa8310f
40 N8168ef0fc73546939f1d401fa7b52742
41 sg:journal.1297400
42 schema:name SPIRE – combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial
43 schema:pagination 216
44 schema:productId N8baf568cd29f421ea921e3b561bd5cf4
45 Nba20b978486141ca9bbe66a3176c0408
46 Ned2a2e2a18644edcbebed5b73c9b0600
47 Nf4437d774340488aa1e4718c29b92b9a
48 Nf8e717cf9cbd4d4a996b57b4b37ca9bc
49 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103148487
50 https://doi.org/10.1186/s13063-018-2586-7
51 schema:sdDatePublished 2019-04-15T09:08
52 schema:sdLicense https://scigraph.springernature.com/explorer/license/
53 schema:sdPublisher N6626867ea61f43f39edb2ed1fe1a5eb8
54 schema:url https://link.springer.com/10.1186%2Fs13063-018-2586-7
55 sgo:license sg:explorer/license/
56 sgo:sdDataset articles
57 rdf:type schema:ScholarlyArticle
58 N2fd6eb681d4e4c1e998e0af6c0f26387 rdf:first sg:person.010355406303.65
59 rdf:rest N7994d58cf16a4e6992bd99489e072440
60 N30e7cc054a454b7eacaa9b169973be20 rdf:first sg:person.010035506562.01
61 rdf:rest N9fdf925d1d044dc3834a198441a10934
62 N37b07ab5aa544916903881b45eb48594 rdf:first N6e36d6dd4a3b4d4f976bf26ea9a285c9
63 rdf:rest N65a570ccd6b84afebe3da3b11e716a1d
64 N4860764eeafd4aa2ba04b2c3dffb3a37 rdf:first sg:person.016540557762.70
65 rdf:rest N30e7cc054a454b7eacaa9b169973be20
66 N4d22e6fc79af41ff92b68953caa8310f schema:issueNumber 1
67 rdf:type schema:PublicationIssue
68 N51fbf77ebb32436a8d24c78476f83673 rdf:first sg:person.01067561552.17
69 rdf:rest N4860764eeafd4aa2ba04b2c3dffb3a37
70 N6127859b3d81412fa6b1c0e698220e4d rdf:first sg:person.01205711374.10
71 rdf:rest Nef27e93655044fe0b853c9daf276cf47
72 N65a570ccd6b84afebe3da3b11e716a1d rdf:first sg:person.012226030162.48
73 rdf:rest N784593ee51f9487381b8fbd603be80be
74 N6626867ea61f43f39edb2ed1fe1a5eb8 schema:name Springer Nature - SN SciGraph project
75 rdf:type schema:Organization
76 N6e36d6dd4a3b4d4f976bf26ea9a285c9 schema:affiliation https://www.grid.ac/institutes/grid.5491.9
77 schema:familyName Ellis
78 schema:givenName Deborah
79 rdf:type schema:Person
80 N784593ee51f9487381b8fbd603be80be rdf:first Nacc32cb22e8d45cd990b2cf82ac0dd63
81 rdf:rest N2fd6eb681d4e4c1e998e0af6c0f26387
82 N7994d58cf16a4e6992bd99489e072440 rdf:first sg:person.07427543430.33
83 rdf:rest Nf7c1dec419a241c1aabaf3409d0168cc
84 N8168ef0fc73546939f1d401fa7b52742 schema:volumeNumber 19
85 rdf:type schema:PublicationVolume
86 N8baf568cd29f421ea921e3b561bd5cf4 schema:name doi
87 schema:value 10.1186/s13063-018-2586-7
88 rdf:type schema:PropertyValue
89 N9fdf925d1d044dc3834a198441a10934 rdf:first N9fe82d9e56a548caa78b5208bf13239b
90 rdf:rest N37b07ab5aa544916903881b45eb48594
91 N9fe82d9e56a548caa78b5208bf13239b schema:affiliation https://www.grid.ac/institutes/grid.5491.9
92 schema:familyName Rajaram
93 schema:givenName Jessica
94 rdf:type schema:Person
95 Nacc32cb22e8d45cd990b2cf82ac0dd63 schema:affiliation https://www.grid.ac/institutes/grid.5491.9
96 schema:familyName Hathorn
97 schema:givenName David
98 rdf:type schema:Person
99 Nba20b978486141ca9bbe66a3176c0408 schema:name pubmed_id
100 schema:value 29615077
101 rdf:type schema:PropertyValue
102 Nce4af51b3ad3486baf91d8f38a4ceaee rdf:first sg:person.015145616762.40
103 rdf:rest N51fbf77ebb32436a8d24c78476f83673
104 Ned2a2e2a18644edcbebed5b73c9b0600 schema:name dimensions_id
105 schema:value pub.1103148487
106 rdf:type schema:PropertyValue
107 Ned724784e9ad4bd4a411685780436869 rdf:first sg:person.0745007670.05
108 rdf:rest rdf:nil
109 Nef27e93655044fe0b853c9daf276cf47 rdf:first sg:person.0727040356.35
110 rdf:rest Nf6a2cbe8f6854e808c30f25bb32ee1be
111 Nf4437d774340488aa1e4718c29b92b9a schema:name readcube_id
112 schema:value 231725dcbfe8dee320517b7c97f34b17b1dcadd64d0894bc713fb4000b163998
113 rdf:type schema:PropertyValue
114 Nf6a2cbe8f6854e808c30f25bb32ee1be rdf:first sg:person.013571313737.52
115 rdf:rest Nce4af51b3ad3486baf91d8f38a4ceaee
116 Nf7c1dec419a241c1aabaf3409d0168cc rdf:first sg:person.0607741761.89
117 rdf:rest Ned724784e9ad4bd4a411685780436869
118 Nf8e717cf9cbd4d4a996b57b4b37ca9bc schema:name nlm_unique_id
119 schema:value 101263253
120 rdf:type schema:PropertyValue
121 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
122 schema:name Medical and Health Sciences
123 rdf:type schema:DefinedTerm
124 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
125 schema:name Oncology and Carcinogenesis
126 rdf:type schema:DefinedTerm
127 sg:grant.5137510 http://pending.schema.org/fundedItem sg:pub.10.1186/s13063-018-2586-7
128 rdf:type schema:MonetaryGrant
129 sg:journal.1297400 schema:issn 1468-6708
130 1745-6215
131 schema:name Trials
132 rdf:type schema:Periodical
133 sg:person.010035506562.01 schema:affiliation https://www.grid.ac/institutes/grid.5491.9
134 schema:familyName Dunkley
135 schema:givenName Denise
136 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010035506562.01
137 rdf:type schema:Person
138 sg:person.010355406303.65 schema:affiliation https://www.grid.ac/institutes/grid.5491.9
139 schema:familyName Whitehead
140 schema:givenName Amy
141 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010355406303.65
142 rdf:type schema:Person
143 sg:person.01067561552.17 schema:affiliation https://www.grid.ac/institutes/grid.423286.9
144 schema:familyName Lowder
145 schema:givenName James N.
146 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067561552.17
147 rdf:type schema:Person
148 sg:person.01205711374.10 schema:affiliation https://www.grid.ac/institutes/grid.5491.9
149 schema:familyName Crabb
150 schema:givenName Simon
151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01205711374.10
152 rdf:type schema:Person
153 sg:person.012226030162.48 schema:affiliation https://www.grid.ac/institutes/grid.5491.9
154 schema:familyName Hill
155 schema:givenName Stephanie
156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012226030162.48
157 rdf:type schema:Person
158 sg:person.013571313737.52 schema:affiliation https://www.grid.ac/institutes/grid.11835.3e
159 schema:familyName Catto
160 schema:givenName James W. F.
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013571313737.52
162 rdf:type schema:Person
163 sg:person.015145616762.40 schema:affiliation https://www.grid.ac/institutes/grid.11485.39
164 schema:familyName McDowell
165 schema:givenName Cathy
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015145616762.40
167 rdf:type schema:Person
168 sg:person.016540557762.70 schema:affiliation https://www.grid.ac/institutes/grid.5491.9
169 schema:familyName Caddy
170 schema:givenName Joshua
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016540557762.70
172 rdf:type schema:Person
173 sg:person.0607741761.89 schema:affiliation https://www.grid.ac/institutes/grid.18886.3f
174 schema:familyName Huddart
175 schema:givenName Robert
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607741761.89
177 rdf:type schema:Person
178 sg:person.0727040356.35 schema:affiliation https://www.grid.ac/institutes/grid.11835.3e
179 schema:familyName Danson
180 schema:givenName Sarah J.
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0727040356.35
182 rdf:type schema:Person
183 sg:person.07427543430.33 schema:affiliation https://www.grid.ac/institutes/grid.5491.9
184 schema:familyName Kalevras
185 schema:givenName Mihalis
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07427543430.33
187 rdf:type schema:Person
188 sg:person.0745007670.05 schema:affiliation https://www.grid.ac/institutes/grid.5491.9
189 schema:familyName Griffiths
190 schema:givenName Gareth
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0745007670.05
192 rdf:type schema:Person
193 sg:pub.10.1038/sj.bjc.6603482 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041715325
194 https://doi.org/10.1038/sj.bjc.6603482
195 rdf:type schema:CreativeWork
196 https://app.dimensions.ai/details/publication/pub.1078479667 schema:CreativeWork
197 https://doi.org/10.1016/j.eururo.2005.04.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041745561
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1016/j.exphem.2012.06.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020992592
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1016/j.urology.2007.11.029 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017900311
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1016/j.urolonc.2009.09.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008466352
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1016/s1470-2045(15)00038-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016223038
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1016/s1470-2045(17)30576-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091339395
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1056/nejmoa022148 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017518186
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1056/nejmoa1613683 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083846671
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1089/cbr.2012.1303 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059243296
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1093/jnci/95.5.399 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032079551
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1128/aac.06161-11 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036456002
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1158/0008-5472.can-09-3427 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012230767
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1158/0008-5472.can-11-3909 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026504828
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1158/1078-0432.ccr-13-2805 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006902149
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1200/jco.2000.18.17.3068 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074702294
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1200/jco.2005.07.757 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028324313
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1200/jco.2007.10.8688 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042356249
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1200/jco.2007.12.7712 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046116901
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1200/jco.2010.32.3139 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048003021
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1371/journal.pone.0032750 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045055578
236 rdf:type schema:CreativeWork
237 https://doi.org/10.2174/1574885511005010017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069214672
238 rdf:type schema:CreativeWork
239 https://doi.org/10.3892/ijmm.2012.1138 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071507284
240 rdf:type schema:CreativeWork
241 https://doi.org/10.3892/ijo.2011.1049 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071512325
242 rdf:type schema:CreativeWork
243 https://doi.org/10.3892/ijo.2014.2792 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071513765
244 rdf:type schema:CreativeWork
245 https://doi.org/10.4161/15384047.2014.986967 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072288033
246 rdf:type schema:CreativeWork
247 https://doi.org/10.4161/epi.4.3.8694 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072302907
248 rdf:type schema:CreativeWork
249 https://doi.org/10.7326/0003-4819-158-3-201302050-00583 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073713447
250 rdf:type schema:CreativeWork
251 https://www.grid.ac/institutes/grid.11485.39 schema:alternateName Cancer Research UK
252 schema:name Cancer Research UK, London, UK
253 rdf:type schema:Organization
254 https://www.grid.ac/institutes/grid.11835.3e schema:alternateName University of Sheffield
255 schema:name Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Sheffield, UK
256 Academic Urology Unit, The Medical school, University of Sheffield, Sheffield, UK
257 rdf:type schema:Organization
258 https://www.grid.ac/institutes/grid.18886.3f schema:alternateName Institute of Cancer Research
259 schema:name The Institute of Cancer Research, Sutton, UK
260 rdf:type schema:Organization
261 https://www.grid.ac/institutes/grid.423286.9 schema:alternateName Astellas Pharma (United States)
262 schema:name Astex Pharmaceuticals, Inc., Pleasanton, CA, USA
263 rdf:type schema:Organization
264 https://www.grid.ac/institutes/grid.5491.9 schema:alternateName University of Southampton
265 schema:name Southampton Clinical Trials Unit, Centre for Cancer Immunology, University of Southampton, Southampton, UK
266 Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK
267 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...